focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,166.00
Bid: 12,132.00
Ask: 12,136.00
Change: -6.00 (-0.05%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

13 May 2015 15:00

RNS Number : 0910N
AstraZeneca PLC
13 May 2015
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

AstraZeneca PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

The Capital Group Companies, Inc.

4. Full name of shareholder(s)  (if different from 3.):iv

See Schedule A

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

11 May 2015

6. Date on which issuer notified:

12 May 2015

7. Threshold(s) that is/are crossed orreached: vi, vii

Above 3%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

(ISIN: GB0009895292)

32,100,333

32,100,333

32,139,533

2.544%

ADRs

(ISIN: US0463531089)

5,767,760

5,767,760

5,768,891

0.457%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

37,908,424

3.000%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

See Schedule A

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Martin Bennett, Assistant Company Secretary

15. Contact telephone number:

020 7604 8157

 

 

Schedule A

As of 11 May 2015

 

AstraZeneca PLC

 

Number of Shares

Percent of Outstanding

The Capital Group Companies, Inc. ("CG") holdings

37,908,424

3.000%

Holdings by CG Management Companies and Funds:

Capital Guardian Trust Company

5,439,762

0.431%

Capital International Limited

165,000

0.013%

Capital International Sàrl

153,792

0.012%

Capital International, Inc.

72,300

0.006%

Capital Research and Management Company

32,077,570

2.539%

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBXGDUCSBBGUX
Date   Source Headline
19th Apr 20227:00 amRNSEnhertu granted Priority Review for HER2m NSCLC
1st Apr 20223:00 pmRNSTotal Voting Rights
29th Mar 20227:00 amRNSOndexxya approved in Japan for FXai reversal
28th Mar 20227:00 amRNSEvusheld approved in the EU for COVID-19
25th Mar 20223:30 pmRNSDirector/PDMR Shareholding
24th Mar 20226:00 pmRNSEvusheld Positive EU CHMP Opinion
24th Mar 20227:00 amRNSUpdate on CALLA Phase III trial for Imfinzi
23rd Mar 202211:00 amRNSNotice of AGM
17th Mar 20227:00 amRNSSettlement of patent litigation for Ultomiris
14th Mar 20227:05 amRNSLynparza approved in US for early breast cancer
14th Mar 20227:00 amRNSUpdate on US review of Fasenra in nasal polyps
9th Mar 20223:30 pmRNSDirector/PDMR Shareholding
7th Mar 20223:30 pmRNSDirector/PDMR Shareholding
1st Mar 20223:30 pmRNSDirector/PDMR Shareholding
1st Mar 20223:00 pmRNSTotal Voting Rights
1st Mar 20227:00 amRNSAstraZeneca and Neurimmune close deal for NI006
23rd Feb 20227:00 amRNSFiling of Form 20-F with SEC
22nd Feb 202211:00 amRNSChair succession planning update and Annual Report
21st Feb 20227:00 amRNSEnhertu improves PFS and OS in HER2-low BC
16th Feb 20227:00 amRNSSaphnelo approved in EU for SLE
15th Feb 20227:00 amRNSLynparza combo delays progression risk in prostate
11th Feb 20223:30 pmRNSDirector/PDMR Shareholding
10th Feb 20227:00 amRNSAZN: Full year and Q4 2021 results
1st Feb 20223:00 pmRNSTotal Voting Rights
19th Jan 20227:05 amRNSImfinzi improves survival in biliary tract cancer
19th Jan 20227:00 amRNSImfinzi combo shows unprecedented survival in HCC
17th Jan 20227:00 amRNSEnhertu granted Priority Review for breast cancer
7th Jan 20227:00 amRNSAstraZeneca and Neurimmune sign deal for NI006
5th Jan 20227:00 amRNSTransfer of rights to Eklira, Duaklir completed
4th Jan 20223:00 pmRNSTotal Voting Rights
29th Dec 20217:00 amRNSAstraZeneca and Ionis close eplontersen deal
21st Dec 20217:00 amRNSUltomiris accepted for FDA Priority Review for gMG
20th Dec 20217:05 amRNSTezspire approved in the US for severe asthma
20th Dec 20217:00 amRNSSaphnelo recommended for EU approval for SLE
15th Dec 20213:00 pmRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSEvusheld US FDA EUA
7th Dec 20217:00 amRNSAstraZeneca, Ionis to collaborate on eplontersen
1st Dec 20213:00 pmRNSBlock listing Interim Review
1st Dec 20213:00 pmRNSTotal Voting Rights
30th Nov 20217:00 amRNSLynparza granted FDA Priority Review for OlympiA
15th Nov 20214:00 pmRNSDirector/PDMR Shareholding
12th Nov 20217:00 amRNSAZN: Year to date and Q3 2021 results
1st Nov 20213:00 pmRNSTotal Voting Rights
1st Nov 20217:00 amRNSAstraZeneca to transfer rights to Eklira, Duaklir
25th Oct 20217:00 amRNSImfinzi improved survival in biliary tract cancer
18th Oct 20217:00 amRNSAZ recommends ADS holders reject mini-tender offer
15th Oct 20217:00 amRNSImfinzi & tremelimumab improved OS in liver cancer
11th Oct 20217:00 amRNSAZD7442 PhIII trial positive in COVID outpatients
4th Oct 20217:00 amRNSEnhertu granted BTD for breast cancer
1st Oct 20213:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.